Dr. Osborne Discusses Targeting the HER2 Pathway in Breast Cancer

C. Kent Osborne, MD
Published: Monday, Apr 17, 2017



C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

Osborne says that chemotherapy may be avoidable by blocking the HER2 pathway with targeted therapies. Along with his collegues, Osborne hypothesizes that it would be more effective to use more targeted agents to block the pathway, as trastuzumab (Herceptin) cannot block all of the receptors alone.

Studies were then done using dual HER2-targeted therapies without chemotherapy with pathologic complete remission rates ranging between 20% and 40%, suggesting that some patients with HER2 overexpressing tumors may not need to undergo chemotherapy at all.
 
SELECTED
LANGUAGE


C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

Osborne says that chemotherapy may be avoidable by blocking the HER2 pathway with targeted therapies. Along with his collegues, Osborne hypothesizes that it would be more effective to use more targeted agents to block the pathway, as trastuzumab (Herceptin) cannot block all of the receptors alone.

Studies were then done using dual HER2-targeted therapies without chemotherapy with pathologic complete remission rates ranging between 20% and 40%, suggesting that some patients with HER2 overexpressing tumors may not need to undergo chemotherapy at all.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x